Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Establishment Labs Holdings Inc. (ESTA:NASDAQ), powered by AI.
Establishment Labs Holdings Inc. is currently trading at $82.14. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Establishment Labs Holdings Inc. on Alpha Lenz.
Establishment Labs Holdings Inc.'s P/E ratio is -47.6.
“Establishment Labs Holdings Inc. trades at a P/E of -47.6 (undervalued) with modest ROE of -133.3%.”
Ask for details →Establishment Labs Holdings Inc. is a medical technology company engaged in the design, development, manufacturing, and marketing of innovative breast implants and body shaping products. The company's main purpose is to advance aesthetics and reconstruction surgeries by providing safe, effective, and high-quality medical devices. Establishment Labs operates notably within the healthcare industry, impacting sectors such as cosmetic surgery, reconstructive surgery, and healthcare innovation. The company offers proprietary features including its use of state-of-the-art Motiva Implants, which are known for their enhanced silicone gel properties and advanced surface technology aimed at reducing complications and enhancing patient satisfaction. Headquartered in Alajuela, Costa Rica, Establishment Labs has established a significant presence in the global market, particularly in Latin America, Europe, and Asia, through its extensive distribution network. It plays a crucial role in setting new standards for patient safety and aesthetic outcomes within the plastic surgery realm, contributing to the medical technology industry's growth and evolution.
“Establishment Labs Holdings Inc. trades at a P/E of -47.6 (undervalued) with modest ROE of -133.3%.”
Ask for details →Establishment Labs Holdings Inc. (ticker: ESTA) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 1,056 employees. Market cap is $2.4B.
The current price is $82.14 with a P/E ratio of -47.65x and P/B of 103.32x.
ROE is -133.25% and operating margin is -18.48%. Annual revenue is $211M.